There is a class of drugs called “Phosphodiesterase-5 inhibitors” (PDE5 inhibitors.) Such drugs in this class are known as sildenafil, vardenafil, tadalafil, and avanafil.1 These drugs all work by ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

Erectile dysfunction drugs were associated with reduced risk of Alzheimer's disease, electronic health record (EHR) data from 270,000 men in the U.K. suggested. Over a median follow-up of about 5 ...

(HealthDay News) — Use of phosphodiesterase type 5 (PDE5) inhibitors does not appear to increase the risk of melanoma, according to the conclusions of a meta-analysis published online in the Journal ...

CHICAGO -- The two most popular medications for erectile dysfunction (ED) may confer substantial cardiovascular benefits for men with ED and concurrent heart disease, according to an analysis of a ...

CORVALLIS, Ore., May 8, 2025 /PRNewswire/ -- Karma Biosciences announced today that it has applied for patent protection for two new drug formulations utilizing its proprietary excipient Zenergy™ .

Men taking phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction (ED) have lower risks of overall MACE, cardiovascular mortality, and all-cause mortality than those not on these ...

For men with a history of myocardial infarction or PCI, it may be risky to use nitrates for angina and phosphodiesterase-5 (PDE5) inhibitors for erectile dysfunction at the same time, a large Swedish ...

Men with primary organic erectile dysfunction (ED) are less likely than those with primary psychogenic ED to adhere to treatment with PDE5 inhibitors. Men with primary organic erectile dysfunction (ED ...

Vivus, Inc, a developer of innovative pharmaceutical products to improve quality of life, has been awarded Patent No. 6,403,597 entitled, "Administration of Phosphodiesterase Inhibitors for the ...